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The enzyme complex c-secretase generates amyloid b-peptide (Ab), a 37–43-residue peptide associ-
ated with Alzheimer disease (AD). Mutations in presenilin 1 (PS1), the catalytical subunit of c-secre-
tase, result in familial AD (FAD). A unifying theme among FAD mutations is an alteration in the ratio
Ab species produced (the Ab42/Ab40 ratio), but the molecular mechanisms responsible remain elu-
sive. In this report we have studied the impact of several different PS1 FAD mutations on the inte-
gration of selected PS1 transmembrane domains and on PS1 active site conformation, and whether
any effects translate to a particular amyloid precursor protein (APP) processing phenotype. Most
mutations studied caused an increase in the Ab42/Ab40 ratio, but via different mechanisms. The
mutations that caused a particular large increase in the Ab42/Ab40 ratio did also display an impaired
APP intracellular domain (AICD) formation and a lower total Ab production. Interestingly, seven
mutations close to the catalytic site caused a severely impaired integration of proximal transmem-
brane/hydrophobic sequences into the membrane. This structural defect did not correlate to a par-
ticular APP processing phenotype. Six selected FAD mutations, all of which exhibited different APP
processing proﬁles and impact on PS1 transmembrane domain integration, were found to display an
altered active site conformation. Combined, our data suggest that FAD mutations affect the PS1
structure and active site differently, resulting in several complex APP processing phenotypes, where
the most aggressive mutations in terms of increased Ab42/Ab40 ratio are associated with a decrease
in total c-secretase activity.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The presence of senile plaques and neuroﬁbrillary tangles in
cerebral cortex and hippocampus are the main neuropathological
hallmarks of Alzheimer disease. Processes leading to plaque and
tangle formation result in neuronal loss in the affected brain areas.
The senile plaques are composed of extracellular aggregates of the
small secreted amyloid b-peptide (Ab) [1] that can range from
37–43 amino acids in length [2]. Ab is derived from the amyloid
precursor protein (APP), which is sequentially cleaved by the
membrane bound b- and c-secretases [3]. Simultaneously, the
APP intracellular domain (AICD) is released into the cytosol.
Ab40 and Ab42 are the most common forms of Ab, where the
Ab42 peptide is more prone to aggregate and form soluble dimers,
394 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406oligomers, protoﬁbrills and eventually insoluble plaques [4–6]. The
soluble forms are implied to be the toxic species that causes
synaptic and neuronal damage as well as impaired memory and
long-term potentiation in the rodent brain [7–9].
The multiprotein complex, c-secretase is an unusual intramem-
brane-cleaving aspartyl protease composed of presenilin (PS), nic-
astrin, Pen-2 and Aph-1 [10–14]. PS is a highly conserved
membrane protein with nine transmembrane domains (TMDs)
and it harbours the catalytic site with the two conserved aspartate
residues that are located in TMD6 and 7 [13,15–18]. Once all com-
ponents are assembled, the PS molecule becomes activated by
endoproteolysis, generating an N-terminal and a C-terminal frag-
ment (NTF and CTF). c-Secretase hydrolyzes its substrate within
the hydrophobic TMDs, which require access to water molecules
in the catalytic site [19].
Currently, more than 185 autosomal dominantly inherited
familial AD (FAD) causing mutations have been identiﬁed in PS1,
13 in PS2 and 33 in APP, strongly suggesting that an altered Ab
metabolism plays a pivotal role in AD pathogenesis. Most PS FAD
mutations are situated within or ﬂanking the conserved hydropho-
bic TMDs and are, except for theDexon9 mutation, missense muta-
tions resulting in single amino acid changes or deletion of two
amino acid residues. In general, FAD mutations in PS1 and 2 cause
an increase in Ab42/Ab40 ratio, either by decreasing the produc-
tion of Ab40 or by increasing the Ab42 generation [20–24]. Previ-
ously, Takami et al presented an Ab product line-model where
APP is sequentially cleaved after every third or fourth amino acid
by c-secretase, depending on the initial e-cleavage site [25].
Recently, Cháves-Gutiérraz et al studied six FAD PS1 mutations’
impact on e- and c-cleavage sites and reported that they impaired
the fourth cleavage site in both Ab40 (AICD50–99 + Ab49 > Ab46 >
Ab43 > Ab40) and Ab42 (AICD49–99 + Ab48 > Ab45 > Ab42 > Ab38)
product lines and thus gave increased Ab42/Ab40 ratio [26]. The
altered Ab42/Ab40 ratio appears to be a very important determi-
nant; both for the process for amyloidosis and for disease onset
[21,27]. In this report, we have performed an even more extensive
study and examined 13 different PS1 FAD mutations and their
effect on the production of ﬁve APP processing products: Ab38,
Ab40, Ab42, Ab43 and AICD.
The topology of a membrane protein is largely dependent on
the hydrophobicity of the TMDs and the charged residues ﬂanking
the TMDs play an important role during insertion into the mem-
brane [28]. Most eukaryotic membrane proteins, including the
human PS1, are co-translationally integrated into the endoplasmic
reticulum (ER) membrane by the Sec61 translocon [29,30]. The
translocon recognizes the hydrophobic TM sequences and allows
them to partition into the membrane while hydrophilic loops
are translocated into the ER lumen or retained in the cytosol
[31]. However, in some cases the TM sequences of multi-spanning
membrane proteins fail to be recognized (marginally hydrophobic
TMs) and need assistance from other parts of the protein for efﬁ-
cient integration and folding [32–34]. Previously, by introducing
glycosylation acceptor sites into the molecule and measuring the
glycosylation status, it has been shown that PS1 contains nine
TMDs [16]. Here we report how efﬁciently each PS1 wild type
TM segment is recognized and inserted into the membrane by
the translocon, by engineering them into the model protein leader
peptidase (Lep) [35,36]. Moreover, we have selected 35 disease-
related PS1 FAD mutations and studied whether the insertion pro-
cess is affected in terms of efﬁciency in targeting and recognition
in comparison to the wild type protein. Finally, we have analyzed
how six out of 35 FAD mutants affected the conformation of the
catalytic site of PS1, using an active site inhibitor pull-down
method.2. Results
2.1. PS FAD mutations differentially affect Ab42/40 ratio, Ab38, Ab43
and AICD production
In order to get a deeper understanding of the mechanisms
behind PS1 FADmutations, we selected 13 different FADmutations
scattered throughout the protein, and transiently transfected them
into cells deﬁcient for PS1 and PS2 (BD8), to nullify the inﬂuence of
endogenous PS. It has previously been reported that generally all
PS FAD mutations have the same phenotype regarding elevation
of the Ab42/Ab40 ratio [20–24,26]. Here we extend these studies
by looking at more Ab products and AICD generation in order to
get a clearer understanding of the PS1 FAD mutations role in APP
processing. The selected mutations were located in TM2, TM3,
TM6, H7 and TM7; some have been studied previously by other
research groups (L166P, A246E, Dexon9, G384A and F386S) and
others have not been examined in this context before. All PS1 pro-
tein variants were expressed and endoproteolysed with the excep-
tion for the Dexon9 mutant which lacks the endoproteolytic site
[37] (Fig. 1A). When measuring Ab38, Ab40 and Ab42 generation
by MSD technology, we observed that all mutations increased the
Ab42/Ab40 ratio to different extent, except for the A246E mutant
that did not affect the ratio compared to PS1 wild type (Fig. 1B).
This is consistent with previously published results [20–24,26].
The highest ratios were generated by the L166P and G384A
mutants that gave rise to substantially elevated levels compare
to PS1 wild type, 7.3 and 6.0 times, respectively. In addition,
I143T, L392P and Dexon9 increased the Ab42/Ab40 ratio, with
4.4, 3.6 and 3.2 times, respectively. Interestingly, the L166P,
I143T, L392P and G384A mutations, also had a pronounced
decrease in Ab40, with a minimum of 50% reduction compared to
wild type. Moreover, these mutations, except L166P, had elevated
Ab42 levels and especially G384A increased Ab42 (four times com-
pared to wild type) (Fig. 1C). The rest of the mutations were more
homogeneous, displaying an increased Ab42/Ab40 ratio ranging
from 1.2-2.6 in relation to wild type and had a similar pattern in
the Ab40 and Ab42 distribution (Fig. 1B and C). However, the
Ab38 values were more similar between the FAD mutations. All,
except A246E and L250S, showed a reduction in Ab38 levels (39–
79% of wild type) (Fig. 1C). Only six of all FAD mutations showed
Ab43 values, above the detection limit of 0.62pM (WT, E280A,
P284L, Dexon9, G384A, F386S and S390I). All, except E280A and
F386S, showed increased Ab43/Ab40 ratio compared to wild type.
The most pronounced increase was for P284L and G384A (6.1
and 14 times increase compared to wild type, respectively)
(Fig. 1D).
Next, we characterized the FADmutations further by examining
their overall effect on c-secretase activity by monitoring AICD pro-
duction from the e-cleavage site by using a Luciferase-reporter
gene assay [38]. In line with a recent report from Chávez-Gutiérrez
et al. [26] and Bentahir et al. [22], we observed that not all FAD
mutations affect AICD formation. Most mutations that we investi-
gated showed no decrease in AICD formation, except I143T, L166P,
Dexon9 and G384A, which all lowered the production (Fig. 1E). The
most impaired production was observed for L166P that reduced
AICD formation to 20% compared to wild type. In addition, I143T,
Dexon9 and G384A decreased the AICD formation with 30–40%
in comparison to PS1 wild type. Overall, the PS1 FAD mutations
decreased the formation of the smaller Ab peptides, Ab38 and
Ab40, in favor to the production of the longer forms (Ab42 and
Ab43), suggesting an impairment in the fourth cleavage sites of
both Ab product lines. However, the PS1 FAD mutations with a
Ab42/Ab40 ratio above 3.2, (L392P, I143T, L166P, Dexon9, G384A,
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Fig. 1. PS1 FAD mutations differentially affect Ab42/Ab40 ratio and the AICD processing. (A) Expression levels of PS1 NTF, CTF, Nicastrin, Pen-2 in PS/ BD8 cells expressing
PS1 WT, I143T, L166P, A246E, L250S, E280A, P284L, Dexon9, R377M, G384A, F386S, S390I, L392P or L392V. All PS1 FAD mutants are expressed to a similar extent and
subjected to endoproteolysis with the exception for the Dexon9 mutant that lacks the endoproteolytic site. (B–C) Conditioned media from BD8 cells expressing PS1 WT or the
mutant forms were analyzed for levels of secreted Ab38, Ab40 and Ab42 species using MSD technology. (B) The Ab42/Ab40 ratio and (C) the levels of Ab38, Ab40 and Ab42 are
plotted in relative to PS1 WT Flag. (D) Conditioned media from BD8 cells expressing PS1 WT and six FAD mutations (E280A, P284L, Dexon9, G384A, F386S and S390I) were
used to determine the Ab43/Ab40 ratio using ELISA. The other mutations were below detection limit. (E) Lysates from BD8 cells expressing PS1 WT and the 13 FAD mutations
were monitored with a Luciferase-based reporter gene assay for AICD production using transfected C99-GVP, MH100, and CMV-b-gal constructs. The transfection efﬁciency
was determined by b-gal activity and the mean value for PS1 wt was set to normalization factor 1, and the FAD mutants in relation to this factor (>1 or <1). The Ab values from
each mutant from the standard curve were then divided with its normalization factor to get the normalized Ab value. The relative Ab value (%) for each mutant to PS1 wt was
calculated by dividing Ab normalized from PS1 FAD mutant with normalized Ab from PS1wt and multiply with 100. Bars represent mean of 3–7 experiments with error bars
indicating S.E. Statistical signiﬁcance is calculated by the non-parametric Mann–Whitney U test. ⁄p < 0.05, ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
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site), indicating that this could contribute to the aggressive pathol-
ogy and early onset of the disease in these FAD patients.
2.2. Efﬁcient membrane integration of all TMDs in PS1, except H7 and
TMD7
One proposed mechanism of PS FAD mutations is a conforma-
tional change of PS1. This could be a three dimensional structural
change of the PS molecule in the catalytic site [39,40] due to
altered membrane integration of the TMD segment that harbours
the mutation. To explore how PS1 FAD-linked mutations affect
the translocon mediated membrane insertion of PS1, we intro-
duced each TM segment with their respective ﬂanking residues
into the well-characterized Escherichia coli inner membrane pro-
tein Lep [35,36,41,42]. Lep has two hydrophobic domains (H1and H2) and a large C-terminal periplasmic domain (P2). When
expressed in vitro in the presence of rough microsomes (rough
ER membrane vesicles, RM) it adopts its natural topology,
Nout–Cout, with its N- and C-terminus in the microsomal ER lumen
[43]. In vitro translation supplemented with ER membranes is a
well established system where the membrane proteins are efﬁ-
ciently targeted to the ER membrane with the help of the signal
recognition particle (SRP) and its receptor. The proteins are inte-
grated into the membrane and glycosylated during translation.
The glycosylation status can be used to study the topology of the
protein. The introduction of the PS1 TMDs was based on the
nine-TM topology model of PS1 [15–18]. In order to study PS1
TMDs in their natural orientation, we used two versions of Lep.
In the ﬁrst version called LepH2, H2 (Nin–Cout orientation) was
replaced by the PS1 TMD of interest and in the second version,
LepH3, the selected TMD was introduced into the P2 domain of
396 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406LepH3 (Nout–Cin orientation) [35,36]. To investigate the efﬁciency
of translocon-mediated membrane insertion, two N-linked glyco-
sylation sites were engineered in LepH2 (G1, G2) and LepH3 (G2,
G3) (Fig. 2A). In cases where a TMD-segment replaces the H2 TM
helix (LepH2 constructs), a fraction of the molecules is often
cleaved into a smaller fragment (fc) in the presence of CRMs
(Fig. 2B–D). Cleavage is prevented by addition of a signal peptidase
inhibitor during translation, resulting in a concomitant increase inBA
F
D
C
G1 G2 G2
G3
ER lumen
cytosol
LepH2 LepH3
P2
H1
P2
H2H1 TMD TMD
   TMD1       TMD2      TMD3      TMD4               TMD5   
     1       2      3      4      5      6      7       8               9     10 
CRM:               - +        -  +         - +       -      +                   - +   
Mr
46 -
30 -
Integration:              86%          100%         84%          88% 90%
Mr
46 -
30 -
1         2       
CRM:                - +       
WT       L2
TMD6   
Integration:                 81%        3
-
30 
- 46 
Mr 1       2      3        4         
TMD7
Endo H:        - - +          
CRM:            -        +       +        +   
*
0
20
40
60
80
100
TMD6 WT
TMD6 L250S
H7 WT
H7 P2
81
38
6
45
%
 M
em
br
an
e 
in
te
gr
at
io
n
E
-
Mock
-
Fig. 2. Model protein Lep and FAD-linked mutations within the TM domains. (A) The
transmembrane helices (H1 and H2) and a large lumenal domain (P2). Lep integrate
orientation. RMs are used because during translation membrane proteins are efﬁciently t
are integrated into the membrane by the translocon and glycosylated during translation
helix (LepH2) or into the P2 domain of Lep (LepH3) to conserve the natural orientation o
even numbered helices into the LepH3 construct. Engineered Asn-X-Thr glycosylation acc
(G2 and G3). Constructs in which the PS1 TMD-segment is integrated into the endoplas
constructs) or on the G2 site (LepH3 constructs). (B) Membrane integration of TMD7 and
protein species, cleaved by the signal peptidase (showed as a pairs of scissors). (C) In vi
(rough ER-vesicles, CRMs) [68] of constructs containing different PS1 TMDs. (D) In vit
glycosylation of TMD7. (E) In vitro translation of selected FAD-linked mutations with
glycosylated, and doubly glycosylated forms of the protein are indicated by one open ci
fragment is indicated by an asterisk (⁄). The percentage of molecules in which the TMD
independent experiments). (F) Membrane integration of PS1 TMD-segments with and wi
is shown. Bars represent mean of three experiments with error bars indicating S.E.the fraction of doubly glycosylated molecules [36]. The signal pep-
tidase active site is located close to the lumenal surface of the ER
membrane [36] and the processed form thus originates from mol-
ecules in which the TMD-segment is inserted into the membrane
and the P2 domain is in the lumen [44]. Fractions of singly (f1x)
and doubly (f2x) glycosylated species were quantiﬁed in order to
calculate an apparent equilibrium constant Kapp, for the membrane
insertion of the given TMD-segment. For LepH3, Kapp is calculated    TMD6         H7         TMD7                 TMD 8  TMD9
    11    12    13    14    15    16               17     18    19     20
    -  +     -  +         -  +                    -   +          -    +
*
81% 6% 47% 100% 84%
 3         4       5       6           7        8        9       10      11     12      13       
 +        -    +       +            - +         +        +        +        +         + 
50S         WT      P284L        WT      R377M F386S S390I L392P L392V
                     H7 TMD7 
*
8% 6%       45%         47%        27%      0%    70%     1%     26%       
G1 G2
ER lumen
cytosol
LepH2
P2
H1 TMD
TMD7 WT
TMD7 F386S
TMD7 S390I
TMD7 L392P
84L
47
1
70
26
TMD7 L392V
TMD7 R377M
27
0
*
leader peptidase (Lep) model proteins, LepH2 and LepH3. Wild type Lep has two
s into dog pancreas rough microsomes (rough ER-vesicles, RMs) in an Nlum–Clum
argeted to the ER membrane with the help of SRP and the SRP receptor. The proteins
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J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406 397as Kapp ¼ f1xf2x and for LepH2, the fractions of cleaved fc molecules
were taken into account as well (if necessary) as Kapp ¼ f2xþfcf1x . Kapp
can be converted into apparent free energies, DGapp ¼ RT lnKapp,
between the inserted and non-inserted states [35,36,41]. We pre-
dicted the DGapp value for PS1 TMD1-9, including their ﬂanking
residues of PS1 by a computational model provided by the DG pre-
diction server (http://www.cbr.su.se/DGpred/). When possible, 20
residues of the ﬂanking region were included followed by two tet-
rapeptides (GGPG. . .GPGG) in order to avoid inﬂuence from the Lep
sequence (Table 1). Our results show that all TMDs of PS1 integrate
efﬁciently into the membrane by the translocon (TMD1: 86%;
TMD2: 100%; TMD3: 84%; TMD4: 88%; TMD5: 90%; TMD6: 81%;
TMD8: 100%; TMD9: 84%), except for the hydrophobic domain 7
(H7) in the large hydrophilic loop 6 (HL6) (H7: 6%) and TMD7
(47%) (Table 1, Fig. 2C). Both H7 and TMD7 code for low integration
efﬁciency in their proposed natural orientation and therefore, weTable 1
Predicted vs. measured DG values for each of the hydrophobic domains in PS1 wild type. P
together with the ﬂanking region and the two-tetra peptides, GGPG. . .GPGG. The integra
indicated in blue.
aTMD segments were predicted from full length PS1 with DG predictor.
#The predicted DG values were determined by the DG prediction server (http://www.cbalso determined their insertion efﬁciency in the other orientation
(LepH2 vs LepH3), and some variations in translocon mediated
insertion efﬁciency was found (H7 increased from 6% to 33%,
TMD7 decreased from 47% to 14%). It seems likely that H7 in HL6
is involved in the endoproteolysis [45,46], probably as a reentrant
loop [47,48], and integrates more efﬁciently in the H3 Nout–Cin ori-
entation (increases to 33%). By contrast, TMD7, which harbours one
of the two catalytic aspartate residues, integrates less efﬁciently in
the H3 Nout–Cin orientation (decreases to 14%). The preferred orien-
tation and the difference in insertion efﬁciency could be due to the
charged residues ﬂanking the TMD and the length and the hydro-
phobicity of the PS1 segment [28,32]. Importantly, the partial inte-
gration of TMD7 is consistent with results reporting that only half
the TMD7 is integrated as an a-helix [49,50]. Moreover, as a con-
trol, glycosylation of TMD7 was conﬁrmed by Endo H-treatment
(Fig. 2D).redicted TMD is indicated in red and the number in () correlate with the TM segment
tion is calculated from at least three independent experiments. N405Q mutation is
r.su.se/DGpred/).
398 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–4062.3. FAD mutations around the catalytic site inﬂuence membrane
integration efﬁciency
To further investigate how PS1 FAD mutations inﬂuence the
insertion into the membrane by the translocon, we analyzed
35 PS1 FAD mutations located in the 10 hydrophobic domains
of PS1. Several non-conservative TM mutations of PS1 belongTable 2
Predicted vs. measured DG values for each FAD mutations of the hydrophobic domains o
integration is calculated from double samples and the most prominent ones from at leastto the eight hydrophobic TMDs (TMD1-6, 8-9) that code for efﬁ-
cient insertion into the membrane, but some are found in hydro-
phobic domains that are not inserted efﬁciently into the
membrane (H7, TMD7) (Table 2). Our result showed, that seven
PS1 FAD mutations affected the insertion efﬁciency with P20%.
Six of the seven substitutions were located in two of the margin-
ally hydrophobic segments, H7 (P284L), and TMD7 (R377M,f PS1. Predicted TMD is indicated in red and FAD mutation is indicated in blue. The
three independent experiments.
Table 2 (continued)
aTMD segments were predicted from full length PS1 with DG predictor.
⁄Mutations are from the Alzheimer Disease and Frontotemporal Dementia Mutation Database (http://www.molgen.ua.ac.be/admutations/).
#The predicted DG values were determined by the DG prediction server (http://www.cbr.su.se/DGpred/).
J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406 399F386S, S390I, L392P, L392V), and one was located in the more
efﬁciently integrated TMD6 (L250S) (Fig. 2E and F). The most
prominent changes were: L250S (TMD6) which had a change
in membrane integration by 43% (from 81% to 38%); P284L
(H7) which had an increase from 6% to 45%; and two mutationsin TMD7, F386S and L392P, which gave rise to a decrease from
47% to 0% and 1%, respectively (Table 2, Fig. 2E and F). Taken
together, this experiment shows that the TMDs facing the cata-
lytic site are affected by FAD mutations in terms of membrane
integration.
Table 3
PS1 FAD mutations with their age of onset, Ab42/Ab40 ratio and% membrane integration.
Region Mutation Age of onset (years)* Ab42/Ab40 ratio change from WT Membrane integration change from WT (%)
TMD2 I143T 34.0 4.4 0
TMD3 L166P 24.0 7.3 2
TMD6 A246E 52.5 1.2 13
TMD6 L250S 52.2 1.7 43
H7 E280A 47.4 2.0 +16
H7 P284L 32.0 1.9 +39
HL6 Dexon9 45.5 3.2 0
TMD7 R377M 39 1.4 20
TMD7 G384A 34.9 6.0 +12
TMD7 F386S 37–58 [70] 2.6 47
TMD7 S390I 39–49 [71] 1.9 +23
TMD7 L392P 38.3 3.6 46
TMD7 L392V 42.5 2.3 21
* Mutations and data are from the Alzheimer Disease and Frontotemporal Dementia Mutation Database (http://www.molgen.ua.ac.be/admutations/), except for the indicated
publications.
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Fig. 3. Topology mapping based on the predicted TM segments of (A) TMD2N and TMD2N (I143T), (B) TMD3N and TMD3N (L166P), (C) TMD3C and TMD3C (L166P), (D)
TMD7C and TMD7C (G384A). The dotted line shows the number of residues required between the acceptor site and either end of the TM segment (12.9 residues for TMD2N/
TMD2N I143T, 15.7 residues for TMD3N/TMD3N L166P, 12.6 residues for TMD3C/TMD3C L166P, 4.5 residues for TMD7C and 4.7 residues for TMD7C G384A) for half-maximal
glycosylation, also indicated by an arrow in the sequence below the graph. The residues in red are the predicted membrane embedded TMDs and the star indicates the
experimentally result where the TM segments starts or ends. The letter in blue is the residues that have been mutated and its position in the sequence. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
400 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406According to our results, I143T (TMD2), L166P (TMD3) and
G384A (TMD7) substitutions did not show any effect in membrane
integration in contrast to the results from the Ab42/Ab40 ratioexperiments, which showed a 4–7 fold increase in the ratio
(Fig. 1B and Table 3). We hypothesize that, while these mutations
do not disrupt or change the TM domains’ efﬁciency in anchoring
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J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406 401to the membrane, they might accommodate differently in the lipid
environment. To test our assumption, we introduced acceptor sites
at different positions relative to the membrane in the wild type TM
and its mutant based on the well-deﬁned distance between the oli-
gosaccharyl transferase active site and the end of the TM segment
[51]. The minimal glycosylation distance (MGD) that is required for
half-maximal glycosylation is approximately 14 residues away
from the N-terminal end and 10 residues away from the C-terminal
end of the TM helix [47,52].
Furthermore, the proline (L166P in TMD3), that could cause a
shift in the membrane, is located in the cytosolic side of the mem-
brane [53]. In order to capture any effect on that side we intro-duced TMD3 and its mutant in the other orientation, in LepH3.
The MGD values were determined for each construct and none of
the mutations showed a difference in position relative to the mem-
brane surface compared to the wild type TM segment. This indi-
cates that the mutations do not affect accommodation of the
TMDs in the lipid environment (Fig. 3A–D).
2.4. PS1 FAD mutations cause changes in the catalytic site
Since not all PS1 FAD mutations caused a change in membrane
integration, especially the mutants with a high Ab42/Ab40 ratio
(>4), (I143T, L166P and G384A), other mechanisms are probably
402 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406also involved in the increased Ab42/Ab40 ratio. One mechanism
could be changed conformation in the catalytic site and one way
to investigate this is to use afﬁnity capture with a c-secretase tran-
sition state analogue inhibitor such as L-685,458. Membranes from
BD8 cells expressing six selected PS1 FAD mutations were incu-
bated in the presence of L685,458 coupled to a cleavable biotin
group (GCB) followed by incubation with streptavidin beads to
capture the active c-secretase complexes. L-685,458-GCB has pre-
viously been shown to block Ab production with a similar IC50 as L-
685,458 [54]. As a negative control, L-685,458 was added prior to
the biotinylated inhibitor. If the catalytic site was affected by the
PS1 FAD mutants, fewer active c-secretase complexes would be
pulled down compared to PS1 wild type. We selected three muta-
tions that showed no altered membrane integration (I143T, L166P,
G384A) and three that gave rise to a substantial change in mem-
brane integration, either an increase (P284L) or a reduction
(L250S and L392P). Interestingly, after normalizing the pulled-
down fragment to input we found that all six mutations affected
the catalytic site of c-secretase, by a reduction between 40 and
70%, and that the differences do not depend on membrane integra-
tion (Fig. 4A). These results are consistent with a previous study
using a similar approach [40], as well as with reported results from
Berezovska et al. that used a FLIM/FRET assay [39].3. Discussion
More than 185 FAD causing mutations have been identiﬁed in
the PS1 molecule, the catalytic subunit of c-secretase. The FAD
causing mutations, distributed all over the PS1 molecule, cause
an altered Ab production and in most cases an increased Ab42/
Ab40 ratio. However, the mechanism by which they impact the
PS structure and function remains largely elusive. In this report
we have made a thorough effort to compare the impact of several
PS FAD mutations on structural parameters of PS1 and asked
whether it relates to a speciﬁc modulation of the APP/Ab process-
ing cascade.
We selected 13 FAD mutations that provided a substantial cov-
erage of several regions of PS1. Eight of the mutations caused an
increase in Ab42, eleven mutations caused a decrease in Ab40,
and twelve mutations caused a decrease in Ab38. Together, these
results suggest that impaired Ab38, Ab40 and increased Ab42 pro-
duction are common Ab phenotypes of FAD mutations, irrespective
of their spatial location within PS1 or their impact on TMD integra-
tion. One of the mutations, the L250S, resulted in neither an
increase in Ab42 or a decrease in Ab38, but caused a decrease in
Ab40. Thus, considering these three Ab peptides we identiﬁed in
total three FAD mutation-induced Ab proﬁles: a selective decrease
in Ab40; a decrease in both Ab40 and Ab38; and an increase in
Ab42 in combination with a decrease in both Ab38 and Ab40,
respectively. Furthermore, four out of the thirteen FAD mutations
caused a decrease in total Ab and AICD formation, reﬂecting a
FAD-induced partial loss of c-secretase activity. Interestingly,
these mutations (I143T, L166P, Dexon9, G384A) gave rise to a very
high Ab42/40 ratio, which primarily was due to an extraordinary
increase in Ab42 production and/or decrease in Ab40 (Table 3).
Recent progress in understanding APP processing has identiﬁed
several c-secretase mediated cleavage events, which result in dif-
ferent Ab peptides (Ab30-51) as well as several 3- and 4- peptides
and a pentamer and a hexamer [25,55,56]. These ﬁndings have lead
to the ‘‘Ab40 and Ab42 product line hypothesis’’, where the Ab40
product line represent AICD50–99 and Ab49, 46, 43, 40, 37/36 and
34, and the Ab42 product line result in AICD49–99 and Ab48, 45,
42, 39/38 and 34, respectively. According to this model, Ab pep-
tides are generated either in a precursor product manner, where
longer Ab species are immediate substrate for the production ofshorter isoforms or, alternatively, the different reactions take place
independently in a more random manner [56]. According to the
former model, the increase in Ab42 and decrease in Ab40 and
Ab38 would reﬂect an impaired processing of Ab43 to Ab40 and
Ab42 to Ab38. In support for that model we found FAD mutations
causing a decrease in Ab40 to be associated with increased Ab43/
Ab40 ratio, and the increase in Ab42 to be linked to a decrease in
Ab38. There were however also some exceptions. For instance,
the E280A mutation caused a decrease in Ab40 but there was no
increase in Ab43. Moreover, the L166P and A246E mutants did
not affect Ab42 levels, whereas both mutants caused a suppression
of Ab38. The obtained data are therefore largely compatible with
the precursor-product mechanism of Ab generation, but still there
are data that cannot be explained by this simplistic model. It is
noteworthy that recent ﬁndings have identiﬁed ‘‘cross-talk’’
between the Ab40 and 42 product lines and both Ab43 and Ab41
have been shown to be precursors for Ab38 [55,56]. Thus, Ab43
and Ab38 production and turnover may not be directly linked to
Ab40 and Ab42, respectively, andmay explain why there was a lack
of correlation between some Ab peptides as outlined above. It is
interesting that the Ab42 levels remained normal albeit the total
AICD level was decreased by the L166P and I143T mutations. Since
most AICD production stems from the Ab40 product line, this Ab
phenotype may be the consequence of a selective decrease of the
entire Ab40 product line, starting at the e-cleavage, whereas
Ab42 product line processing remains intact. Such a mechanism
was recently suggested by both Chavez-Gutierrez et al, who stud-
ied other PS1 mutations, and by us and others in the context of APP
FAD mutations [26,56,57]. One caveat with our analysis is that we
did not analyse AICD production or smaller c-secretase-derived
peptides with mass spectrometry. Moreover, we have not studied
the longer membrane bound Ab forms such as Ab45 and Ab46.
Such data would clarify many of the questions raised above, but
is beyond the scope of this study.
Given the spread of FAD causing mutations across the entire PS1
molecule, we hypothesized that FAD mutations in general may
give rise to subtle structural changes. Since PS1 is a highly inte-
grated membrane protein, exhibiting nine TMDs, we focused our
studies on exploring the impact of FAD mutations on PS1 mem-
brane integration. Using a membrane integration assay in an
in vitro transcription/translation system based on N-linked glyco-
sylation, we were able to study how efﬁcient each TMD of PS1 inte-
grates independently into the lipid bilayer of the ER membrane. All
TMDs but TMD7 showed a nice membrane integration as would be
expected for true transmembrane spanning sequences. The less
hydrophobic segment TMD7 is not predicted to be a TMD accord-
ing to the DG predictor program, which is mostly based on the
hydrophobicity. These data conﬁrm the proposed general mem-
brane topography of PS1 and also validate the experimental system
to delineate the impact of different PS1 FAD mutations on mem-
brane integration.
We studied in total 35 different FAD mutations, covering all
TMDs, and revealed several novel insights to the structural impact
of FAD mutations on PS. Not surprisingly, the TMD7 is found to be
very sensitive to substitution of amino acid residues, e.g. F386S and
L392P substitutions strongly reduced the insertion that made the
TMD7 incapable to insert independently into the membrane. On
the other hand, we could observe that the more hydrophobic seg-
ment TMD6 is also susceptible for drastic changes. For instance,
substituting the hydrophobic Leu at position 250 to the polar res-
idue Ser decreased the integration efﬁciency by 43%. TMD7 is part
of the hydrophilic catalytic cavity, which is embedded in the
hydrophobic core of the membrane, probably protected and sur-
rounded by the strongly and stable hydrophobic domains
(TMD1-6, TMD8-9). This notion is supported by the recently pub-
lished crystal structure of the PS homologue from the archaeon
J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406 403Methanoculleus marisnigri JR1 [58]. Moreover, the fact that water
must be present in order to cleave membrane protein substrates
suggests that the hydrophilic residues within TMD7 are needed
and important for catalysis. The hydrophilic milieu causes the sub-
strate to unfold, making the backbone amide bonds accessible to
the nucleophilic attack that allows cleavage [59,60]. The predicted
topology program suggests H7 as a weak or marginally hydropho-
bic TMD, but experimental data shows that H7 is not recognized as
a TMD by the translocon, and thereby is not inserted into the mem-
brane. This observation agrees well with the model that H7 reaches
the catalytic site in order get endoproteolysed and not to be situ-
ated in the membrane. The substitution P284L (H7) caused an
increase of insertion efﬁciency from 6% to 45%, which is in line with
that the overall hydrophobicity of the TM segment increases.
Overall, the ﬁndings from the 35 studied PS1 FAD mutations
suggest that some mutations (those located in TMD6, H7 and
TMD7) have either a strong positive or negative impact on mem-
brane integration, whereas other mutations do not appear to affect
membrane integration at all (Tables 1 and 2). Although these stud-
ies are based on insertion efﬁciency of single TMDs and PS1 is a
multispanning-membrane protein possibly inﬂuenced by the other
TMDs in the assembled protein, our data provide an important
insight into the biogenesis of PS1. To conclude, a comparison
between the FAD-induced APP processing phenotypes and the
effect, or lack of effect, on membrane integration of hydrophobic
sequences did not reveal any striking correlation between the phe-
notypes. It is therefore conceivable that the impact of FAD mutants
on PS1 function is complex, and that the abnormal membrane inte-
gration identiﬁed here represents one mechanism.
Three different reports have suggested that PS1 FAD mutations
could alter the catalytic site of c-secretase. Although these studies
are based on only a few PS FAD mutants, they provide an attractive
common molecular rationale to the Ab modulatory effect of FAD
mutations. In order to explore whether an altered active site
indeed is a more general feature associated with FAD mutations,
we selected six mutations that both had a differential impact on
membrane integration and modulated Ab production at different
levels. Thus, we explored both mutations that had a negative effect
on AICD/total Ab production while either exhibiting normal or
increased Ab42 levels, and mutations that did not affect total Ab/
AICD production but both caused an increase in Ab42 and a
decrease in Ab40, or only a decrease in Ab40. Interestingly, neither
of these mutants was pulled-down to the same extent as wt PS1,
using a biotinylated version of the transition state analogue
L685.458. These results suggest that all FAD mutations explored
affect the active site of PS1. Why this common phenotype results
in different Ab modulatory proﬁles remains uncertain, but it is
likely that the pull-down experiment is a rather gross measure-
ment of alterations within the active site, and that different struc-
tural changes in the active site could affect APP processing in
multiple directions.
In summary, we have made a thorough analysis of different PS
FADmutants with regard to pivotal structural aspects and APP pro-
cessing activity of PS1. We have found that the FAD mutants
impact membrane integration in several different ways and to var-
ious extents, and we have also identiﬁed several FAD-induced APP
processing phenotypes that all result in an increased Ab42/Ab40
ratio, which is believed to play a pivotal role in AD pathogenesis.
Most importantly, while we could not identify a speciﬁc correla-
tion between abnormal membrane integration and a particular
APP processing phenotype, our data suggest that an altered
active site of PS1 is a common abnormal structural parameter
that links FAD mutations to pathogenic Ab production (summa-
rized in Fig. 4B). Future studies are warranted to reveal the
linkage between FAD mutations and altered PS1 active site
conformation.4. Experimental procedures
4.1. Antibodies, chemicals and enzymes
The following antibodies were used for immunoblotting: NT-1
recognizing the PS1-NTF [61], a-loop (Chemicon) raised against
PS1-CTF, N1660 (Sigma) raised against the C-terminal of nicastrin,
3891 (ProSci Inc.) raised against Pen-2 and a-GAPDH (Acris GmbH)
recognizing GAPDH. For the quantiﬁcation of secreted Ab38, 40 and
42 with Meso Scale Discovery (MSD) technology, C-terminal spe-
ciﬁc antibodies (Ab 1-x) were used and detection was performed
by SULFO-TAG™ 6E10 antibody. For quantiﬁcation of sectreted
Ab40 and Ab43 using Ab40 Wako II ELISA kit (Wako Chemicals
GmbH) and FL 1-43 ELISA kit (Immuno-biological Laboratories),
respectively, the capture antibody was BNT77 for Ab40 and
Ab38-43 for Ab43. Detection antibodies were BA27 (Ab40) and
82E1 (Ab43), respectively. Unless otherwise stated, all chemicals
were from Sigma–Aldrich. Plasmid pGEM1, TNT Quick transcrip-
tion/translation system, and deoxynucleotides were purchased
from Promega and 35S-Met from PerkinElmer. All enzymes were
obtained from Fermentas except Phusion DNA polymerase that
was from Finnzymes. Oligonucleotides were from Euroﬁns MWG
Operon.
4.2. cDNA constructs
For the membrane integration assay, double-stranded oligonu-
cleotides encoding the human PS1 segments were introduced as
ampliﬁed PCR fragments into the previously described modiﬁed
lepB gene [35,36]. The PS1 fragments were ampliﬁed using the
Phusion DNA polymerase with primers complementary to the
50 and 30 ends of the selected part of the gene and then cloned
into the pGEM1 vector, containing the corresponding lepB gene,
on SpeI/KpnI sites. In order to remove the endogenous glycosyl-
ation acceptor sites found in the PS1 upstream of TM8, Asn405-
Thr-Thr was substituted to Gln405-Thr-Thr. Site-speciﬁc muta-
genesis was performed using the QuikChange™ Site-Directed
Mutagenesis Kit (Stratagene). The ampliﬁed DNA products were
puriﬁed using the QIAquick PCR Puriﬁcation Kit (QIAGEN) and
all inserted fragments and mutants were conﬁrmed by sequenc-
ing at Euroﬁns MWG Operon. For the functionality assays, full-
length PS1 WT with or without a Flag-tag was cloned into the
pcDNA5FRT/TO vector (Invitrogen) on BamHI/NotI sites. cDNAs
encoding Flag-PS1 mutants I143T, L166P, G384A were generated
by site directed mutagenesis using the QuikChange Site Directed
mutagenesis protocol (Stratagene). The mutations, A246E, L250S,
E280A, P284L, R377M, F486S, S390I, L392P and L392V, were gen-
erated with the same protocol as above using PS1 WT without a
Flag-tag as a template. The PS1 Dexon9 deletion mutant has
been described elsewhere [62]. The DNA sequence of all con-
structs was veriﬁed using the BigDye Terminator Version 3.1
Cycle Sequencing kit (Applied Biosystems). The reporter con-
structs MH100, CMV-b-gal and C99-GVP used in the Luciferase-
based Reporter Gene Assay have been described previously
[38,63].
4.3. Cell culture and transfection
Blastocyst-derived embryonic stem cells deﬁcient for PS1 and
PS2, BD8 cells [64], were cultured in ES medium; Dulbecco’s mod-
iﬁed Eagle’s medium supplemented with 10% fetal calf serum,
1 mM sodium pyruvate, 0.1 mM b-mercaptoethanol, and nones-
sential amino acids (Invitrogen). BD8 cells stably expressing APP
WT have been previously generated in our laboratory [65]. The
cDNA constructs were transiently transfected into the cells using
404 J. Wanngren et al. / FEBS Open Bio 4 (2014) 393–406the Lipofectamine 2000 reagent (Invitrogen) according to the man-
ufacturer’s instructions.
4.4. Immunoblotting
Cells were lysed 24–48 h after transfection in cell lysis buffer
(10 mM Tris, pH 8.1, 1 mM EDTA, 150 mM NaCl, 0.65% IGEPAL
CA-630) supplemented with Protease Inhibitor Mixture (Roche
Applied Science). Protein levels were determined by the BCA™
protein assay kit (Pierce), separated on NuPAGE 4–12% gradient
Bis-Tris gels with MES buffer (both Invitrogen), and transferred
to nitrocellulose membranes (Bio-Rad), which were probed with
primary antibody. The blots were developed using horseradish per-
oxidase-conjugated secondary antibodies (GE Healthcare) followed
by Immobilon™ Western chemiluminescent HRP substrate
(Millipore) using Amersham Biosciences HyperﬁlmTM ECL (GE
Healthcare) or the CCD camera LAS-3000 (FUJIFILM Life Science).
In the case of quantiﬁcation, the respective bands were measured
using ImageJ software (National Institutes of Health).
4.5. Quantiﬁcation of secreted Ab
A sandwich immunoassay using the Meso Scale Discovery SEC-
TOR Imager 6000 was used to quantify secreted Ab38, Ab40 and
Ab42 peptides in conditioned medium. All reagents were from
Meso Scale Discovery. The analysis was carried out as described
earlier with small modiﬁcations [65,66]. In brief, BD8 cells stably
expressing human APP WT were transiently transfected with PS1
WT or different FAD mutations. Cells were incubated in fresh med-
ium containing either 1 lM L-685,458 or vehicle (DMSO 0.5%) for
24 h before analysis of the conditioned medium. The correspond-
ing concentrations of Ab peptides in the samples were calculated
using Ab peptide standard curves. To adjust for differences in
transfection efﬁciency, the b-galactosidase activity of the cell
lysate was determined and normalized to the levels of secreted
Ab peptides. Experiments were performed in triplicate and
repeated 4–7 times. For Ab43 analysis FL 1-43 ELISA (Immuno-bio-
logical Laboratories) was used and at the same time Ab40 (human/
rat b-amyloid (40) ELISA kit WakoII (Wako Chemicals GmbH) was
analysed to obtain a ratio between Ab43 and Ab40 for comparison
to Ab42/Ab40 from Meso Scale Discovery analysis. The protocol
was according to the manufacturer’s instructions but with a mod-
iﬁcation in antibody binding quantiﬁcation as described previously
[67]. 50 lM Amplex UltraRed Reagent (Invitrogen) was incubated
for 1 h at room temperature and followed by detection of ﬂuores-
cent signal using 566 nm excitation ﬁlter and 583 nm emission ﬁl-
ter in a microplate reader (TECAN, Saﬁre II). Samples were
measured in duplicates and repeated 4 times.
4.6. Luciferase-based reporter gene assay
BD8 cells were transfected with the cDNA constructs: PS1
WT/mutations/mock, MH100, CMV-b-gal and C99-GVP, lysed
36 h after transfection and then analyzed as previously described
[38]. The c-secretase activity was normalized against the transfec-
tion efﬁciency by determining the b-galactosidase activity of the
cell lysate. Experiments were performed in triplicate and repeated
4–5 times.
4.7. In vitro membrane integration assay
The pGEM1 vectors containing the PS1 fragments were tran-
scribed and translated in the TNT SP6 Quick Coupled System (Pro-
mega) using 10 ll of reticulocyte lysate, 150–200 ng DNA
template, 1 ll of [35S]Met (5 lCi) and 0.5 ll column-washed dog
pancreas rough microsomes (rough ER membrane vesicles, CRMs)(a gift from Arthur E. Johnson [68]) and the samples were incu-
bated for 90 min at 30 C. For Endo H treatment, 6 ll of the TNT
reaction were mixed with 3 ll dH2O and 1 ll of 10 Glycoprotein
Denaturing Buffer. Following addition of; 1 ll of Endo H
(500,000 units/ml; NEB, MA, US) and 7 ll of dH2O as well as 2 ll
of 10 G5 Reaction Buffer, the sample was incubated for 1 h at
37 C. The proteins were analyzed by SDS–PAGE gels and visual-
ized in a Fuji FLA 3000 phosphorImager (Fujiﬁlm) using the Image
Reader V1.8J/Image Gauge V 3.45 software (Fujiﬁlm). The MultiGa-
uge (Fujiﬁlm) software was used to generate a proﬁle of each gel
lane and the multi-Gaussian ﬁt program (Qtiplot, www.qtiplot.ro)
was used to calculate the peak areas of the glycosylated protein
bands. The membrane integration efﬁciency of a given mutant
was determined by normalizing the peak area of the singly or dou-
bly glycosylated band (depending on which Lep construct was
used) to the total area of both singly and doubly glycosylated pro-
tein bands. On average, the glycosylation levels vary by no more
than ±5% between repeated experiments.
4.8. Afﬁnity capture of c-secretase using GCB
To investigate if the FAD mutations affect the conformation of
the catalytic site of the c-secretase, complexes containing FAD
PS1 were pulled down with a c-secretase transition state analogue
inhibitor (L-685,458) coupled to biotin via a cleavable linker (GCB).
The GCB pull down, its structure, and characteristics have been
described earlier [54]. BD8 cells transiently transfected with PS1
WT, I143T, L166P, G384A, L205S, P284L and L392P or untransfec-
ted cells were subjected to membrane preparations and GCB pull
down, as described previously [69]. Brieﬂy, the cells were homog-
enized in homogenization buffer (10 mM KCl and 10 mM MOPS,
pH 7.0, supplemented with PIC) by 25 strokes at 1500 rpm using
a pestle homogenizer. The homogenates were centrifuged at
1000g for 10 min at 4 C and the obtained post-nuclear superna-
tants were centrifuged further at 100,000g for 1 h at 4 C. The
resultant membrane pellets were suspended in homogenization
buffer supplemented with 20% glycerol, ﬂash frozen in liquid nitro-
gen and stored at 80 C prior to use. After membrane preparation,
samples were concentrated using the Amicon Ultra-2 50K device
(Millipore) according to the manufacturer’s instructions and then
subjected to Size-exclusion chromatography in order to purify
the c-secretase components bound in the complex from unbound
components. The samples were injected onto a Superose™ 6 10/
300 GL column (GE Healthcare) and buffer H (20 mM Hepes, pH
7.4, 150 mM NaCl and 2 mM EDTA) supplemented with Protease
Inhibitor Mixture (Roche Applied Science) and 0.5% CHAPSO was
used as the mobile phase at a ﬂow rate of 0.5 ml/min. 0.5 ml frac-
tions were collected from 7 to 30 min, concentrated using the Ami-
con Ultra-2 50K device (Millipore) and analyzed by SDS–PAGE as
described above. After the initial experiment, where the fractions
containing c-secretase components were determined, the four
fractions containing the most c-secretase were pooled and concen-
trated as described before. After removal of an aliquot to use as
input, samples were incubated with 200 nM GCB before the addi-
tion of magnetic streptavidin beads (Invitrogen). As a negative con-
trol, samples were incubated with 10 lM L-685,458 prior to the
addition of GCB. The captured c-secretase components were eluted
with Laemmli sample buffer, analyzed by SDS–PAGE and Western
blotting and related to the amount of input.
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